14. Khan N, Lamb L, Moores R. Clinical features and acute management in adults. In: Fabre A, Hurst JR, Ramjug S, eds. COVID-19 (ERS Monograph). Sheffield, European Respiratory Society, 2021 pp. 101–123. 15. ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 2021 385: 790–802. 16. Gramegna A, Mantero M, Amati F, et al. Post-COVID-19 sequelae. In: Fabre A, Hurst JR, Ramjug S, eds. COVID-19 (ERS Monograph). Sheffield, European Respiratory Society, 2021 pp. 180–196. 17. Lui LMW, Lee Y, McIntyre RS. Economic, physical and social determinants of health during lockdown: a call for renewed societal responses. In: Fabre A, Hurst JR, Ramjug S, eds. COVID-19 (ERS Monograph). Sheffield, European Respiratory Society, 2021 pp. 232–243. 18. Simonds AK, Boyton RJ. Vaccines: immunology, regulation and clinical management. In: Fabre A, Hurst JR, Ramjug S, eds. COVID-19 (ERS Monograph). Sheffield, European Respiratory Society, 2021 pp. 244–260. Disclosures: A. Fabre has nothing to declare. J.R. Hurst reports receiving the following, outside the submitted work: support to attend meetings, and payment for educational and advisory work, both to him and his employer (University College London, London, UK), from pharmaceutical companies that make medicines to treat respiratory disease. S. Ramjug reports receiving the following, outside the submitted work: honoraria from Janssen and Bayer. xii https://doi.org/10.1183/2312508X.10017521